NIH NIDDK SBIR/STTR

NIH NIDDK SBIR/STTR is the small-business funding route of the National Institute of Diabetes and Digestive and Kidney Diseases, one of NIH’s institutes within the U.S. Department of Health and Human Services. NIDDK’s mission covers medical research and training on diabetes, endocrine and metabolic disease, digestive disease, nutritional disorders, obesity, kidney disease, urologic disease, and hematologic disease. The program is a grant mechanism with multiple yearly cycles, and the structured record places awards between US$200,000 and US$2 million, with a median actual award of US$400,000. It requires a U.S.-incorporated for-profit company, excludes nonprofits and individuals, and targets TRL 2-7. NIDDK’s guidance supports Phase I, Phase II, Direct Phase II-SBIR, Phase IIB, Fast-Track, and Commercialization Readiness Pilot applications, with investigator-initiated work typically entering through the omnibus SBIR/STTR solicitations. The captured guidance says NIH had no active SBIR or STTR NOFOs after the April 13, 2026 reauthorization, and the next standard receipt date was forecast for September 5, 2026. NIDDK’s strongest fit is for translational projects that can move from target identification toward clinical testing while staying inside the institute’s disease scope and its three extramural divisions.

No upcoming rounds verified. Cadence: Multiple per year.